BNP Paribas Financial Markets’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $49.7K | Buy |
37,903
+3,093
| +9% | +$4.27K | ﹤0.01% | 4881 |
|
|
2026
Q1 | $55K | Buy |
34,810
+18,868
| +118% | +$31.8K | ﹤0.01% | 4644 |
|
|
2025
Q4 | $26.6K | Buy |
15,942
+15,782
| +9,864% | +$27.3K | ﹤0.01% | 4939 |
|
|
2025
Q3 | $270 | Sell |
160
-3,448
| -96% | -$4.08K | ﹤0.01% | 5362 |
|
|
2025
Q2 | $3.27K | Sell |
3,608
-5,971
| -62% | -$3.54K | ﹤0.01% | 5006 |
|
|
2025
Q1 | $4.33K | Sell |
9,579
-9,520
| -50% | -$5.58K | ﹤0.01% | 4877 |
|
|
2024
Q4 | $9.6K | Buy |
+19,099
| New | +$14K | ﹤0.01% | 4849 |
|
|
2022
Q4 | – | Sell |
-4,209
| Closed | -$4.76K | – | 4347 |
|
|
2022
Q3 | $4.76K | Buy |
+4,209
| New | +$6.18K | ﹤0.01% | 4259 |
|
|
2019
Q3 | – | Sell |
-18,017
| Closed | -$19.8K | – | 4532 |
|
|
2019
Q2 | $19.8K | Sell |
18,017
-7,154
| -28% | -$8.24K | ﹤0.01% | 3898 |
|
|
2019
Q1 | $33K | Buy |
25,171
+21,080
| +515% | +$26.2K | ﹤0.01% | 3729 |
|
|
2018
Q4 | $3.73K | Buy |
4,091
+103
| +3% | +$158 | ﹤0.01% | 3679 |
|
|
2018
Q3 | $8.2K | Buy |
3,988
+60
| +2% | +$126 | ﹤0.01% | 3832 |
|
|
2018
Q2 | $7.08K | Sell |
3,928
-19,553
| -83% | -$39.4K | ﹤0.01% | 3939 |
|
|
2018
Q1 | $55.3K | Sell |
23,481
-7,394
| -24% | -$17.3K | ﹤0.01% | 3513 |
|
|
2017
Q4 | $58.1K | Buy |
30,875
+22,557
| +271% | +$49.3K | ﹤0.01% | 3584 |
|
|
2017
Q3 | $20.4K | Sell |
8,318
-1,239
| -13% | -$3.07K | ﹤0.01% | 3579 |
|
|
2017
Q2 | $26K | Buy |
9,557
+8,532
| +832% | +$23.8K | ﹤0.01% | 3513 |
|
|
2017
Q1 | $2.78K | Sell |
1,025
-470
| -31% | -$1.33K | ﹤0.01% | 3444 |
|
|
2016
Q4 | $4.4K | Sell |
1,495
-4,430
| -75% | -$13.6K | ﹤0.01% | 3756 |
|
|
2016
Q3 | $19.9K | Buy |
5,925
+2,965
| +100% | +$8.19K | ﹤0.01% | 2892 |
|
|
2016
Q2 | $6.52K | Buy |
2,960
+2,833
| +2,231% | +$6.95K | ﹤0.01% | 3133 |
|
|
2016
Q1 | $68 | Sell |
127
-15,143
| -99% | -$33.8K | ﹤0.01% | 2632 |
|
|
2015
Q4 | $49.9K | Sell |
15,270
-1,069
| -7% | -$3.19K | ﹤0.01% | 2813 |
|
|
2015
Q3 | $39.3K | Buy |
16,339
+10,833
| +197% | +$28K | ﹤0.01% | 3032 |
|
|
2015
Q2 | $15.9K | Buy |
5,506
+3,877
| +238% | +$15K | ﹤0.01% | 3192 |
|
|
2015
Q1 | $6.21K | Buy |
1,629
+1,491
| +1,080% | +$5.16K | ﹤0.01% | 3026 |
|
|
2014
Q4 | $117 | Sell |
138
-5,630
| -98% | -$15.2K | ﹤0.01% | 1940 |
|
|
2014
Q3 | $14.6K | Buy |
+5,768
| New | +$13.9K | ﹤0.01% | 3362 |
|
|
2014
Q1 | – | Sell |
-593
| Closed | -$1.72K | – | 3616 |
|
|
2013
Q4 | $1.72K | Buy |
+593
| New | +$1.79K | ﹤0.01% | 3723 |
|
|
2013
Q3 | – | Sell |
-14,467
| Closed | -$46.2K | – | 2649 |
|
|
2013
Q2 | $46.2K | Buy |
+14,467
| New | +$46.3K | ﹤0.01% | 2684 |
|
Other funds holding LCTX
BC
DC
BNP Paribas Financial Markets's LCTX Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Lineage Cell Therapeutics (LCTX) stake by 8.9% in Q2 2026, buying an estimated $4.27K and bringing the position to 37,903 shares worth $49.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4881.
BNP Paribas Financial Markets first reported a position in LCTX in Q2 2013 and has held it in 30 quarters since. The position peaked at $58.1K in Q4 2017. 126 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.
- BNP Paribas Financial Markets held 37,903 shares of Lineage Cell Therapeutics worth $49.7K as of Q2 2026.
- BNP Paribas Financial Markets bought 3,093 Lineage Cell Therapeutics shares in Q2 2026, an estimated $4.27K.
- Lineage Cell Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4881 holding.
- BNP Paribas Financial Markets first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 30 quarters since.
- BNP Paribas Financial Markets's Lineage Cell Therapeutics position peaked at $58.1K in Q4 2017.
- 126 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.